Rosacea
Drug research and approvals for rosacea: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 12 studies of rosacea are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 12
- Trials authorized in Canada: 6
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting Now
Newest start dates first, of 12 recruiting on ClinicalTrials.gov ↗- Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser TherapyNCT07521462 · Not applicable · ISISPHARMA · starts Sep 3, 2026
- Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and…NCT07922668 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Sep 1, 2026
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With…NCT07681271 · Phase 2 · Novartis Pharmaceuticals · starts Jul 30, 2026
- Transcutaneous Auricular Vagus Nerve Stimulation Treatment for RosaceaNCT07600424 · Not applicable · Brigham and Women's Hospital · starts May 23, 2026
- Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept TrialNCT07341087 · Not applicable · King's College London · starts Apr 28, 2026
- Clinical Study of a Facial Cream for RosaceaNCT07637032 · Not applicable · ChinaNorm · starts Apr 28, 2026
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)…NCT07343635 · Not applicable · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · starts Feb 1, 2026
- Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and SafetyNCT07296497 · Not applicable · Xiangya Hospital of Central South University · starts Dec 24, 2025
- Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform RosaceaNCT06952517 · Phase 2 · Narrows Institute for Biomedical Research · starts Mar 14, 2025
- Rosacea Radiofrequency MicroneedlingNCT06801717 · Not applicable · University of Miami · starts Nov 1, 2024
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 20, 2026 | A multicenter, randomized, double-blind, placebo-controlled phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (lou064) in…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Ongoing |
| May 3, 2017 | Efficacy comparison of ivermectin 1% topical cream associated with doxycycline 40 mg modified release (mr) capsules versus ivermectin 1% topical cream…IVERMECTIN/ DOXYCYCLINE | GALDERMA CANADA INC | Closed |
| Sep 28, 2015 | A phase 3 open-label extension study to evaluate the long-term safety of omiganan topical gel in subjects with rosaceaOMIGANAN | CUTANEA LIFE SCIENCES, INC | Closed |
| Sep 28, 2015 | A phase 3, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of a once-daily cls001 topical gel versus…OMIGANAN | CUTANEA LIFE SCIENCES, INC | Closed |
| Sep 28, 2015 | A phase 3, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of a once-daily cls001 topical gel versus…OMIGANAN | CUTANEA LIFE SCIENCES, INC | Closed |
| Oct 8, 2013 | A randomized, double-blind, vehicle controlled study of the safety and efficacy of topical drm02 in subjects with rosaceaDRM02 | DERMIRA INCORPORATED | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 22, 1988 | MetrogelTreatment of acne rosacea. | Galderma Laboratories, Inc. | Approved |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Feb 20, 2014 | Mirvasobrimonidine | Galderma S.A. (Netherlands Branch) | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA